

lymphomas, prurigo, lichen planus, atopic dermatitis, eczema, contact dermatitis, allergic dermatitis, nummular dermatitis, lichen simplex, psoriasis, Sézary syndrome, cutaneous lymphomas, bullous pemphigoid, alopecia areata, scabies, vitiligo, urticaria and drug-induced pruritus; pruritic diseases on non-diseased skin of systemic, neurological or psychosomatic/psychiatric origin, including endocrine and metabolic disorders, infections, haematological and lymphoproliferative diseases, solid neoplasms and drug-induced pruritus; mastocytosis; pruritus of unknown cause; pruritus with chronic secondary scratch lesions, such as prurigo nodularis, and all types of prurigo; or any other dermal disease or condition characterized by pruritus.

19. The compound according to claim 18 wherein the pruritic skin condition is selected from prurigo, lichen planus, atopic dermatitis, eczema, contact dermatitis, allergic dermatitis, nummular dermatitis, lichen simplex, psoriasis, Sézary syndrome, cutaneous lymphomas, urticaria, mastocytosis and pruritus with chronic secondary scratch lesions.

20. A pharmaceutical composition comprising, as a therapeutically active ingredient, a compound according to any one of claims 1-16 and a pharmaceutically acceptable carrier or vehicle.

21. A pharmaceutical composition according to claim 20 together with one or more other therapeutically active compound(s).

22. A pharmaceutical composition according to claims 20-21 suitable for topical administration.


~~23. A method of preventing, treating or ameliorating a condition involving pruritus of the skin, the method comprising applying, on the skin of a patient in need thereof, a therapeutically effective amount of a compound according to any one of claims 1-16, optionally together with a pharmaceutically acceptable carrier or one or more excipients, optionally in combination with other therapeutically active compounds.~~

~~24. A method according to claim 23, wherein the condition is selected from the group consisting of acute pruritus in any condition; chronic pruritus on diseased skin, such as inflammatory, infectious, or autoimmune cutaneous diseases, genodermatoses, drug reactions, dermatoses of pregnancy and skin lymphomas, prurigo, lichen planus, atopic dermatitis, eczema, contact dermatitis, allergic dermatitis, nummular dermatitis,~~

lichen simplex, psoriasis, Sézary syndrome, cutaneous lymphomas, bullous pemphigoid, alopecia areata, scabies, vitiligo, urticaria and drug-induced pruritus; pruritic diseases on non-diseased skin of systemic, neurological or psychosomatic/psychiatric origin, including endocrine and metabolic disorders, infections, haematological and lymphoproliferative diseases, solid neoplasms and drug-induced pruritus; mastocytosis; pruritus of unknown cause; pruritus with chronic secondary scratch lesions, such as prurigo nodularis, and all types of prurigo; or any other dermal disease or condition characterized by pruritus.

2523. The use of a compound according to claims 1-16 in the manufacture of a medicament for the prevention, treatment or amelioration of pruritic skin conditions , e.g. acute pruritus in any condition; chronic pruritus on diseased skin, such as inflammatory, infectious, or autoimmune cutaneous diseases, genodermatoses, drug reactions, dermatoses of pregnancy and skin lymphomas, prurigo , lichen planus, atopic dermatitis, eczema, contact dermatitis, allergic dermatitis, nummular dermatitis, lichen simplex, psoriasis, Sézary syndrome, cutaneous lymphomas, bullous pemphigoid, alopecia areata, scabies, vitiligo, urticaria and drug-induced pruritus; pruritic diseases on non-diseased skin of systemic, neurological or psychosomatic/psychiatric origin, including endocrine and metabolic disorders, infections, haematological and lymphoproliferative diseases, solid neoplasms and drug-induced pruritus; mastocytosis; pruritus of unknown cause; pruritus with chronic secondary scratch lesions, such as prurigo nodularis, and all types of prurigo; or any other dermal disease or condition characterized by pruritus.

2624. A compound according to general formula B



wherein R10 is selected from the group consisting of hydrogen and $-C(O)OR_{14}$;

R11 is selected from the group consisting of hydrogen and oxo;

R12 and R13 are independently selected from the group consisting of hydrogen, C₁-C₄ alkyl, allyl and -C(O)O(C₁-C₄ alkyl) ;

R14 is selected from the group consisting of C₁-C₄ alkyl;

n is 1 or 2;

or a pharmaceutically acceptable salt thereof.

2725. The compound according to claim 2624 selected from the group consisting of

1-(2-methylphenyl)-octahydro-1H-pyrrolo[1,2-a][1,4]diazepin-7-one;

1-(2-methylphenyl)-octahydropyrrolo[1,2-a]piperazin-6-one benzyl N-(2-{2-[(2-methylphenyl)carbonyl]-5-oxopyrrolidin-1-yl}ethyl)carbamate ;

tert-butyl 1-(2-methylphenyl)-6-oxo-octahydropyrrolo [1,2-a]piperazine-2-carboxylate ;

2-tert-butyl 7-methyl 1-(2-methylphenyl)-6-oxo-octahydropyrrolo [1,2-a] piperazine - 2,7 dicarboxylate;

(tert-butyl 1-(2-methylphenyl)-6-oxohexahydropyrrolo[1,2-a]pyrazine-2(1H)-carboxylate);

Methyl 7-methyl-1-(2-methylphenyl)-6-oxo-octahydropyrrolo{1,2-a} piperazine-7-carboxylate;

Methyl 1-(2-methylphenyl)-6-oxo-octahydropyrrolo[1,2-a]piperazine-7-carboxylate ;

tert-butyl 1-(2-methylphenyl)-octahydropyrrolo[1,2-a]piperazine-2-carboxylate;

1-(2-methylphenyl)-octahydropyrrolo[1,2-a]piperazine;

1-(2-methylphenyl)-octahydropyrrolo[1,2-a]piperazin-6-one hydrochloride salt; 2-tert-

butyl 7,7-dimethyl 1-(2-methylphenyl)-6-oxo-octahydropyrrolo[1,2-a]piperazine-2,7,7-tricarboxylate;

7,7-dimethyl 1-(2-methylphenyl)-6-oxo-octahydropyrrolo[1,2-a]piperazine-7,7-dicarboxylate;

tert-butyl 1-(2-methylphenyl)-6-oxo-7,7-bis(prop-2-en-1-yl)-octahydropyrrolo[1,2-a]piperazine-2-carboxylate and

1-(2-methylphenyl)-7,7-bis(prop-2-en-1-yl)-octahydropyrrolo[1,2-a]piperazin-6-one;

or a pharmaceutically acceptable salt thereof.